EcoDrugPlus

Kinase Insert Domain Receptor

Ensembl ID : ENSSHBG00005020156
Gene Symbol: KDR
1 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinesin Family Member 11

Ensembl ID : ENSSHBG00005020449
Gene Symbol: KIF11
1 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinesin Family Member 5b

Ensembl ID : ENSSHBG00005019694
Gene Symbol: KIF5B
3 Cross references
281 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Leukotriene A4 Hydrolase

Ensembl ID : ENSSHBG00005011211
Gene Symbol: LTA4H
3 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lysine Demethylase 1a

Ensembl ID : ENSSHBG00005018833
Gene Symbol: KDM1A
2 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lysine-Specific Histone Demethylase 1a-Like

Ensembl ID : ENSSHBG00005006470
Gene Symbol: LOC115615991
2 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lysyl Oxidase Like 2

Ensembl ID : ENSSHBG00005008682
Gene Symbol: LOXL2
3 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSSHBG00005015728
Gene Symbol: MIF
3 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 1

Ensembl ID : ENSSHBG00005002695
Gene Symbol: MMP1
1 Cross references
364 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 13

Ensembl ID : ENSSHBG00005002584
Gene Symbol: MMP13
1 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 2

Ensembl ID : ENSSHBG00005004868
Gene Symbol: MMP2
2 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 7

Ensembl ID : ENSSHBG00005002758
Gene Symbol: MMP7
3 Cross references
163 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).